Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin

Agreement includes upfront, milestone and royalty payments on future sales

10-Apr-2008 - Lorus Therapeutics Inc. announced today that its subsidiary GeneSense Technologies, Inc. has signed an exclusive multinational license agreement with Zor Pharmaceuticals LLC formed as a subsidiary of Zoticon Bioventures Inc., a research-driven biopharmaceutical group, to further develop and ...

Lorus announces initiation of IND-enabling toxicology studies for its lead small molecule drug, LOR-253

Toxicology studies in preparation for an investigational new drug application to the US FDA

27-Mar-2008 - Lorus Therapeutics Inc. announced the start of GLP toxicology studies for its lead anticancer small molecule drug LOR-253. The toxicology studies, which are currently underway, are designed to support the filing of an Investigational New Drug (IND) application with the U.S. FDA for LOR-253 to ...

Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia

31-Aug-2007 - Lorus Therapeutics Inc. announced completion of a proof of concept clinical trial in Acute Myeloid Leukemia (AML), and expansion of its GTI-2040 development program in this indication, with initiation of a more advanced Phase II clinical trial with GTI-2040 and high dose Ara-C (HiDAC) in ...

Lorus Therapeutics announces the appointment of a new President and Chief Executive Officer

21-Sep-2006 - The board of directors of Lorus Therapeutics Inc. announced that Dr. Aiping H. Young will take the position of President and Chief Executive Officer of Lorus on September 21, 2006, the occasion of the Company's Annual General Meeting. Dr. Young has served at various times as Lorus' ...

Lorus Therapeutics announces the allowance of a United States patent to protect novel anticancer agents

21-Aug-2006 - Lorus Therapeutics Inc. announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent from the United States Patent and Trademark Office for antisense oligonucleotides directed towards the novel cancer target neuropilin, and provided an update on a financing ...

Lorus announces down regulation of GTI-2040 molecular target in breast cancer clinical study

Publication shows rapid reduction in target gene expression in responding tumor tissue

24-Apr-2006 - Lorus Therapeutics Inc. announced publication of data demonstrating decreased expression of the molecular target for its antisense drug, GTI-2040, in a Phase II breast cancer clinical trial. The article titled "Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 ...

Lorus identifies novel class of lead drug candidates from small molecule anticancer program

26-Aug-2005 - Lorus Therapeutics Inc. announced the continued success in the development of its small molecule anticancer program with the selection of a sub-class of lead molecules from the Company's small molecule program. Two molecules from this sub-class, ML-133 and LT-253, have been chosen as lead ...

Lorus signs agreement with Japan's Sumitomo Pharmaceuticals and Koken Co. Ltd.

07-Apr-2005 - Lorus Therapeutics Inc. announced that it has signed a collaboration agreement with Sumitomo Pharmaceuticals Co. Ltd. and Koken Co. Ltd. According to terms of the agreement, Lorus will provide Sumitomo proprietary antisense oligonucleotides complementary to Thioredoxin mRNA, specifically the lead ...

Lorus Therapeutics allowed European patent to protect unique tumor suppressor

02-Jun-2004 - Toronto. Lorus Therapeutics Inc. ("Lorus") announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the European Patent Office for its discovery of a gene, which suppresses the growth of malignant tumors. The patent titled, 'Suppression of ...